93 results on '"Delorme V"'
Search Results
2. Self-assembly of a bioinspired, photoactive-centered nanocontainer for drug delivery
- Author
-
Sonkaria, S., primary, Khare, V., additional, Delorme, V., additional, Purwar, P., additional, and Lee, J., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Trisomie 12 en mosaïque diagnostiquée sur signes d’appel échographiques
- Author
-
Vidal, C., Boulet, S., Delorme, V., and Sergent, F.
- Published
- 2012
- Full Text
- View/download PDF
4. Chapter 9 Redundancy and Crosstalk Within the Thioredoxin and Glutathione Pathways
- Author
-
Reichheld, J.-P., primary, Bashandy, T., additional, Siala, W., additional, Riondet, C., additional, Delorme, V., additional, Meyer, A., additional, and Meyer, Y., additional
- Published
- 2009
- Full Text
- View/download PDF
5. Fragment-sized EthR inhibitors exhibit exceptionally strong ethionamide boosting effect in whole-cell Mycobacterium tuberculosis assays
- Author
-
Nikiforov, P.O., Błaszczyk, M., Surade, S., Boshoff, H.I., Sajid, A., Delorme, V., Deboosere, N., Brodin, P., Baulard, A.R., Barry III, C.E., Blundell, T.L., and Abell, C.
- Abstract
Small-molecule inhibitors of the mycobacterial transcriptional repressor EthR have previously been shown to act as boosters of the second-line antituberculosis drug ethionamide. Fragment-based drug discovery approaches have been used in the past to make highly potent EthR inhibitors with ethionamide boosting activity both in vitro and ex vivo. Herein, we report the development of fragment-sized EthR ligands with nanomolar minimum effective concentration values for boosting the ethionamide activity in Mycobacterium tuberculosis whole-cell assays
- Published
- 2017
6. Cytoplasmic-nuclear male sterility in pearl millet: comparative RFLP and transcript analyses of isonuclear male-sterile lines
- Author
-
Delorme, V., Keen, C. L., Rai, K. N., and Leaver, C. J.
- Published
- 1997
- Full Text
- View/download PDF
7. Molecular diagnosis of recurrent Streptococcus mutans endocarditis by PCR amplification and sequencing
- Author
-
Gauduchon, V., Benito, Y., Célard, M., Mouren, C., Delorme, V., Philippe-Bert, J., Etienne, J., and Vandenesch, F.
- Published
- 2001
8. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell $\textit{Mycobacterium tuberculosis}$ Assays
- Author
-
Nikiforov, PO, Blaszczyk, M, Surade, S, Boshoff, HI, Sajid, A, Delorme, V, Deboosere, N, Brodin, P, Baulard, AR, Barry, CE, Blundell, TL, Abell, C, Blundell, Tom [0000-0002-2708-8992], Abell, Chris [0000-0001-9174-1987], and Apollo - University of Cambridge Repository
- Subjects
Repressor Proteins ,Bacterial Proteins ,Drug Discovery ,Antitubercular Agents ,Drug Synergism ,Microbial Sensitivity Tests ,Mycobacterium tuberculosis ,Enzyme Inhibitors ,Ethionamide ,Ligands - Abstract
Small-molecule inhibitors of the mycobacterial transcriptional repressor EthR have previously been shown to act as boosters of the second-line antituberculosis drug ethionamide. Fragment-based drug discovery approaches have been used in the past to make highly potent EthR inhibitors with ethionamide boosting activity both $\textit{in vitro}$ and $\textit{ex vivo}$. Herein, we report the development of fragment-sized EthR ligands with nanomolar minimum effective concentration values for boosting the ethionamide activity in $\textit{Mycobacterium tuberculosis}$ whole-cell assays.
- Published
- 2017
- Full Text
- View/download PDF
9. ATR3 encodes a diflavin reductase essential for Arabidopsis embryo development
- Author
-
Varadarajan, J., Guilleminot, J., Saint-Jore-Dupas, C., Piegu, Benoit, Chabouté, M.E., Gomord, V., Coolbaugh, R.C., Devic, M., Delorme, V., Laboratoire Génome et développement des plantes (LGDP), Université de Perpignan Via Domitia (UPVD)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie moléculaire des plantes (IBMP), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), and Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2010
10. Crystal structure of the M. tuberculosis sulfate ester dioxygenase Rv3406 in complex with iron.
- Author
-
Neres, J., primary, Hartkoorn, R.C., additional, Chiarelli, L.R., additional, Gadupudi, R., additional, Pasca, M., additional, Mori, G., additional, Farina, D., additional, Salina, S., additional, Makarov, V., additional, Kolly, G.S., additional, Molteni, E., additional, Binda, C., additional, Dhar, N., additional, Ferrari, S., additional, Brodin, P., additional, Delorme, V., additional, Landry, V., additional, de Jesus Lopes Ribeiro, A.L., additional, Saxena, P., additional, Pojer, F., additional, Venturelli, A., additional, Carta, A., additional, Luciani, R., additional, Porta, A., additional, Zanoni, G., additional, De Rossi, E., additional, Costi, M.P., additional, Riccardi, G., additional, and Cole, S.T., additional
- Published
- 2014
- Full Text
- View/download PDF
11. Chimérisme tétragamétique : à propos d’un cas
- Author
-
Loriaux, A., primary, Boulet, S., additional, Delorme, V., additional, Althuser, M., additional, Giroud Lathuile, C., additional, Grego, S., additional, Amblard, F., additional, Dupuis, C., additional, Schaal, J.-P., additional, and Jouk, P.-S., additional
- Published
- 2011
- Full Text
- View/download PDF
12. Étude des circonstances de naissance prématurée avant 35SA dans le sillon alpin : étude PREMALP
- Author
-
Delorme, V., primary, Bal, G., additional, Equy, V., additional, David-Tchouda, S., additional, Arnould, P., additional, Abraham, L., additional, Cans, C., additional, and Debillon, T., additional
- Published
- 2010
- Full Text
- View/download PDF
13. A novel peptide that regulates cell death in the Arabidopsis suspensor
- Author
-
Young, B., primary, Gallois, P., additional, Delorme, V., additional, and Blanvillain, R., additional
- Published
- 2007
- Full Text
- View/download PDF
14. A functional S locus anther gene is not required for the self-incompatibility response in Brassica oleracea.
- Author
-
Pastuglia, M, primary, Ruffio-Châble, V, additional, Delorme, V, additional, Gaude, T, additional, Dumas, C, additional, and Cock, J M, additional
- Published
- 1997
- Full Text
- View/download PDF
15. A matrix metalloproteinase gene is expressed at the boundary of senescence and programmed cell death in cucumber.
- Author
-
Delorme, V G, McCabe, P F, Kim, D J, and Leaver, C J
- Abstract
Cell-cell and extracellular cell matrix (ECM) interactions provide cells with information essential for controlling morphogenesis, cell-fate specification, and cell death. In animals, one of the major groups of enzymes that degrade the ECM is the matrix metalloproteinases (MMPs). Here, we report the characterization of the cucumber (Cucumis sativus L. cv Marketmore) Cs1-MMP gene encoding such an enzyme likely to play a role in plant ECM degradation. Cs1-MMP has all the hallmark motif characteristics of animal MMPs and is a pre-pro-enzyme having a signal peptide, propeptide, and zinc-binding catalytic domains. Cs1-MMP also displays functional similarities with animal MMPs. For example, it has a collagenase-like activity that can cleave synthetic peptides and type-I collagen, a major component of animal ECM. Cs1-MMP activity is completely inhibited by a hydroxamate-based inhibitor that binds at the active site of MMPs in a stereospecific manner. The Cs1-MMP gene is expressed de novo at the end stage of developmental senescence, prior to the appearance of DNA laddering in cucumber cotyledons leaf discs and male flowers. As the steady-state level of Cs1-MMP mRNA peaks late in senescence and the pro-enzyme must undergo maturation and activation, the protease is probably not involved in nutrient remobilization during senescence but may have another function. The physiological substrates for Cs1-MMP remain to be determined, but the enzyme represents a good candidate for plant ECM degradation and may be involved in programmed cell death (PCD). Our results suggest that PCD occurs only at the culmination of the senescence program or that the processes are distinct with PCD being triggered at the end of senescence.
- Published
- 2000
- Full Text
- View/download PDF
16. Plant programmed cell death: A common way to die
- Author
-
Danon, A., Delorme, V., Mailhac, N., and Gallois, P.
- Published
- 2000
- Full Text
- View/download PDF
17. Characterization of clinically significant isolates of Staphylococcus epidermidis from patients with endocarditis
- Author
-
Etienne, J, Brun, Y, el Solh, N, Delorme, V, Mouren, C, Bes, M, and Fleurette, J
- Abstract
Biotyping, slime production, bacteriophage typing, serotyping, antibiograms, and plasmid profiles were used to characterize 19 Staphylococcus epidermidis strains isolated from 12 patients with prosthetic valve endocarditis and from 7 patients with native valve endocarditis. With the API Staph battery, 12 different biocodes with, at the most, three differences were obtained. Slime production was found for 10 strains (53%). Agglutinogens investigated by agglutination with two specific sera were found for 12 strains (63.1%). Three strains were phage typable (15.2%). Against a panel of nine antimicrobial agents, 15 different profiles were found. Multiply antibiotic-resistant strains were isolated from patients with prosthetic valve endocarditis when disease onset occurred less than 18 months after heart surgery and from patients with native valve endocarditis who received antibiotics immediately prior to their illness. All of the strains were available for plasmid analysis, and all the DNA profiles were distinct. On gels run in Tris-borate buffer, 73.7% of the strains had large plasmids of more than 30 megadaltons. A small plasmid of 2.8 megadaltons was found in multiply resistant strains and in strains resistant only to tetracyclines. None of the isolates appeared to be the same strain, and the bacteriological differences between the strains were confirmed mainly by the antibiotic susceptibility profile and the plasmid pattern analysis. These bacteriological results were in agreement with the clinical data.
- Published
- 1988
- Full Text
- View/download PDF
18. Explication du sens en classe de langue : le rôle du contexte
- Author
-
Delorme Vera
- Subjects
Social Sciences - Abstract
Cette communication propose de mettre en lumière les pratiques par lesquelles s'effectue l'explication du sens par le contexte dans les interactions verbales en classe de langue (français langue étrangère). Les pratiques en question – qui sont à la fois discursives et didactiques – consistent à construire un contexte fictionnel ou réel autour d’un élément à transmettre, pouvant être un mot, une expression ou encore un acte langagier, dans le but d’illustrer le sens de ce dernier. A travers l’analyse des transcriptions des interactions en classe de FLE (public adulte) on mettra en évidence la diversité des moyens discursifs que les participants à l’interaction didactique utilisent dans la construction des contextes et on proposera la description du fonctionnement de ces derniers que l’on développera d'une part en nous appuyant sur la conceptualisation du contexte en linguistique interactionnelle, et d'autre part à partir de la notion du cadre de l’expérience (Goffman). Concernant ce dernier point, on insistera sur le fait que les « prémisses organisationnelles » des cadres jouent un rôle crucial dans la transmission des connaissances à travers la construction discursive des contextes car, d’une part, ils représentent les mécanismes qui permettent d’interpréter une situation construite et de ce fait, d’accéder au sens d’un élément à transmettre, et d’autre part, ces schèmes interprétatifs peuvent eux-mêmes faire partie du contenu à enseigner/apprendre. En outre, on soulignera que, dans la mesure où les cadres s’inscrivent dans la culture d’un groupe social donné, les contextes construits dans le discours véhiculent inévitablement une part de culturel.
- Published
- 2012
- Full Text
- View/download PDF
19. Evaluation of the API 20 STREP system for species identification of streptococci associated with infective endocarditis.
- Author
-
Etienne, J., Reverdy, M. E., Gruer, L. D., Delorme, V., and Fleurette, J.
- Abstract
A rapid commercial system (API 20 STREP gallery, API System, France) for the identification of streptococci was compared with conventional biochemical or serological methods. 77 clinical isolates from patients with infective endocarditis and six reference strains were tested.Biochemical tests showing differences between conventional methods and the API gallery were the acidification of inulin and the Voges-Proskauer reaction, but these differences did not affect the final identification of any strain. 75 strains were identified by the API system and 70 by conventional methods. 69 strains (25 groupable and 44 of 51 non-groupable streptococci) were given the same identity by both methods. One S. morbillorum was only identified by the conventional method. Seven S. sanguis I strains were identified only by the API system and confirmed by additional biochemical tests. The API gallery is a useful method for identifying streptococci associated with infective endocurditis, agreeing with conventional methods in 90% of strains. Results are usually available in 24 h. [ABSTRACT FROM PUBLISHER]
- Published
- 1984
- Full Text
- View/download PDF
20. Redundancy and Crosstalk Within the Thioredoxin and Glutathione Pathways: A New Development in Plants.
- Author
-
Reichheld, J.-P., Bashandy, T., Siala, W., Riondet, C., Delorme, V., Meyer, A., and Meyer, Y.
- Subjects
- *
THIOREDOXIN , *GLUTAREDOXIN , *GLUTATHIONE , *CHEMICAL reduction , *PLANT growth - Abstract
The article focuses on the thioredoxins (Trx) and glutaredoxins (Grx) pathways in plants. It cites that Trx and Grx are involved in biological processes and both have their respective reduction system. The NADPH Trx system (NTS) is consists of redox cascade including NADPH, Trx reductase (NTR) and Trx. Meanwhile, NADPH Grx system (NGS) comprises NADPH, glutathione reductase (GR), glutathione (GSH) and Grx. It notes that NTS and NGS act in parallel and do have several common target proteins.
- Published
- 2009
- Full Text
- View/download PDF
21. Synthesis of a New Poly(ε-caprolactone)-g-Chitosan Amphiphilic Graft Copolymer with a "Reverse" Structure.
- Author
-
Delorme V, David G, Dejean S, Mouton J, Garric X, Coudane J, and Van Den Berghe H
- Subjects
- Polymers, Polyesters chemistry, Polyethylene Glycols chemistry, Chitosan chemistry
- Abstract
Hydrophilic chitosan (CHT) and hydrophobic polyε-caprolactone (PCL) are well-known biocompatible and biodegradable polymers that have many applications in the biomedical and pharmaceutical fields. But the mixtures of these two compounds are considered incompatible, which makes them not very interesting. To avoid this problem and to further extend the properties of these homopolymers, the synthesis of a new graft copolymer, the fully biodegradable amphiphilic poly(ε-caprolactone-g-chitosan) (PCL-g-CHT) is described, with an unusual "reverse" structure formed by a PCL backbone with CHT grafts, unlike the "classic" CHT-g-PCL structure with a CHT main chain and PCL grafts. This copolymer is prepared via a copper-catalyzed 1,3-dipolar Huisgen cycloaddition between propargylated PCL (PCL-yne) and a new azido-chitosan (CHT-N
3 ). In order to obtain an amphiphilic copolymer regardless of the pH, chitosan oligomers, soluble at any pH, are prepared and used. The amphiphilic PCL-g-CHT copolymer spontaneously self-assembles in water into nanomicelles that may incorporate hydrophobic drugs to give novel drug delivery systems., (© 2023 Wiley-VCH GmbH.)- Published
- 2023
- Full Text
- View/download PDF
22. Mycobacterium tuberculosis induces delayed lipid droplet accumulation in dendritic cells depending on bacterial viability and virulence.
- Author
-
Costa MFS, Pereira-Dutra F, Deboosere N, Jouny S, Song OR, Iack G, Souza AL, Roma EH, Delorme V, Bozza PT, and Brodin P
- Subjects
- Lipid Droplets, Virulence, Microbial Viability, BCG Vaccine metabolism, Dendritic Cells metabolism, Dendritic Cells microbiology, Mycobacterium tuberculosis genetics
- Abstract
Tuberculosis remains a global health threat with high morbidity. Dendritic cells (DCs) participate in the acute and chronic inflammatory responses to Mycobacterium tuberculosis (Mtb) by directing the adaptive immune response and are present in lung granulomas. In macrophages, the interaction of lipid droplets (LDs) with mycobacteria-containing phagosomes is central to host-pathogen interactions. However, the data available for DCs are still a matter of debate. Here, we reported that bone marrow-derived DCs (BMDCs) were susceptible to Mtb infection and replication at similar rate to macrophages. Unlike macrophages, the analysis of gene expression showed that Mtb infection induced a delayed increase in lipid droplet-related genes and proinflammatory response. Hence, LD accumulation has been observed by high-content imaging in late periods. Infection of BMDCs with killed H37Rv demonstrated that LD accumulation depends on Mtb viability. Moreover, infection with the attenuated strains H37Ra and Mycobacterium bovis-BCG induced only an early transient increase in LDs, whereas virulent Mtb also induced delayed LD accumulation. In addition, infection with the BCG strain with the reintroduced virulence RD1 locus induced higher LD accumulation and bacterial replication when compared to parental BCG. Collectively, our data suggest that delayed LD accumulation in DCs is dependent on mycobacterial viability and virulence., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
23. Biolum' RGB: A Low-Cost, Versatile, and Sensitive Bioluminescence Imaging Instrument for a Broad Range of Users.
- Author
-
Boitet M, Eun H, Achek A, Carla de Almeida Falcão V, Delorme V, and Grailhe R
- Subjects
- Luminescent Proteins metabolism, Diagnostic Imaging, Smartphone
- Abstract
Luminometer and imaging systems are used to detect and quantify low light produced by a broad range of bioluminescent proteins. Despite their everyday use in research, such instruments are costly and lack the flexibility to accommodate the variety of bioluminescence experiment formats that may require top or bottom signal acquisition, high or medium sensitivity, or multiple wavelength detection. To address the growing need for versatile technologies, we developed a highly customizable bioluminescence imager called Biolum' RGB that uses a consumer color digital camera with a high-aperture lens mounted at the bottom or top of a 3D-printed dark chamber and can quantify bioluminescence emission from cells grown in 384-well microplates and Petri dishes. Taking advantage of RGB detectors, Biolum' RGB can distinguish spectral signatures from various bioluminescence probes and quantify bioluminescence resonant energy transfer occurring during protein-protein interaction events. Although Biolum' RGB can be used with any smartphone, in particular for low bioluminescence signals, we recommend the use of recent digital cameras which offer better sensitivity and high signal/noise ratio. Altogether, Biolum' RGB combines the benefits of a plate reader and imager while providing better image resolution and faster acquisition speed, and as such, it offers an exciting alternative for any laboratory looking for a versatile, low-cost bioluminescence imaging instrument.
- Published
- 2022
- Full Text
- View/download PDF
24. An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.
- Author
-
Sheikhpour M, Delorme V, Kasaeian A, Amiri V, Masoumi M, Sadeghinia M, Ebrahimzadeh N, Maleki M, and Pourazar S
- Subjects
- Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Bacterial Proteins metabolism, Drug Resistance, Bacterial genetics, Fluoxetine pharmacology, Humans, Isoniazid pharmacology, Isoniazid therapeutic use, Microbial Sensitivity Tests, Mutation, Mycobacterium tuberculosis, Nanoparticles therapeutic use, Tuberculosis drug therapy, Tuberculosis microbiology, Tuberculosis, Multidrug-Resistant microbiology
- Abstract
Drug resistance in tuberculosis is exacerbating the threat this disease is posing to human beings. Antibiotics that were once effective against the causative agent, Mycobacterium tuberculosis (Mtb), are now no longer usable against multi- and extensively drug-resistant strains of this pathogen. To address this issue, new drug combinations and novel methods for targeted drug delivery could be of considerable value. In addition, studies have shown that the use of the antidepressant drug fluoxetine, a serotonin reuptake inhibitor, can be useful in the treatment of infectious diseases, including bacterial infections. In this study, an isoniazid and fluoxetine-conjugated multi-walled carbon nanotube nanofluid were designed to increase drug delivery efficiency alongside eliminating drug resistance in vitro. The prepared nanofluid was tested against Mtb. Expression levels of inhA and katG mRNAs were detected by Real-time PCR. ELISA was applied to measure levels of cytokine secretion (TNF-α, and IL-6) from infected macrophages treated with the nano delivery system. The results showed that these nano-drug delivery systems are effective for fluoxetine at far lower doses than for free drugs. Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb. In addition, it was found that the expression of isoniazid resistance genes, including inhA, katG, and the secretion of cytokines TNFα and IL6 under the influence of this drug delivery system is well regulated. It was shown that the drug conjugation can improve the antibacterial activity of them in all strains and these two drugs have an additive effect on each other both in free and conjugated forms. This nano-drug delivery method combined with host targeted molecules could be a game-changer in the development of a new generation of antibiotics that have high therapeutic efficiencies, low side effects, and the potential to overcome the problem of drug resistance., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
25. The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.
- Author
-
Flipo M, Frita R, Bourotte M, Martínez-Martínez MS, Boesche M, Boyle GW, Derimanov G, Drewes G, Gamallo P, Ghidelli-Disse S, Gresham S, Jiménez E, de Mercado J, Pérez-Herrán E, Porras-De Francisco E, Rullas J, Casado P, Leroux F, Piveteau C, Kiass M, Mathys V, Soetaert K, Megalizzi V, Tanina A, Wintjens R, Antoine R, Brodin P, Delorme V, Moune M, Djaout K, Slupek S, Kemmer C, Gitzinger M, Ballell L, Mendoza-Losana A, Lociuro S, Deprez B, Barros-Aguirre D, Remuiñán MJ, Willand N, and Baulard AR
- Subjects
- Animals, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Ethionamide chemistry, Ethionamide pharmacology, Ethionamide therapeutic use, Mice, Mycobacterium tuberculosis, Prodrugs pharmacology, Prodrugs therapeutic use, Tuberculosis drug therapy
- Abstract
The sensitivity of Mycobacterium tuberculosis , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial moieties. Various oxidases of M. tuberculosis have the potential to activate the prodrug ethionamide. Here, we used medicinal chemistry coupled with a phenotypic assay to select the N-acylated 4-phenylpiperidine compound series. The lead compound, SMARt751, interacted with the transcriptional regulator VirS of M. tuberculosis , which regulates the mymA operon encoding a monooxygenase that activates ethionamide. SMARt751 boosted the efficacy of ethionamide in vitro and in mouse models of acute and chronic TB. SMARt751 also restored full efficacy of ethionamide in mice infected with M. tuberculosis strains carrying mutations in the ethA gene, which cause ethionamide resistance in the clinic. SMARt751 was shown to be safe in tests conducted in vitro and in vivo. A model extrapolating animal pharmacokinetic and pharmacodynamic parameters to humans predicted that as little as 25 mg of SMARt751 daily would allow a fourfold reduction in the dose of ethionamide administered while retaining the same efficacy and reducing side effects.
- Published
- 2022
- Full Text
- View/download PDF
26. A combination screening to identify enhancers of para-aminosalicylic acid against Mycobacterium tuberculosis.
- Author
-
Heo J, Koh D, Woo M, Kwon D, de Almeida Falcão VC, Wood C, Lee H, Kim K, Choi I, Jang J, Brodin P, Shum D, and Delorme V
- Subjects
- Antitubercular Agents chemistry, Humans, Aminosalicylic Acid metabolism, Aminosalicylic Acid pharmacology, Mycobacterium tuberculosis, Tuberculosis, Lymph Node
- Abstract
Para-aminosalicylic acid (PAS) is an antibiotic that was largely used for the multi-therapy of tuberculosis in the twentieth century. To try to overcome the inconvenience of its low efficacy and poor tolerance, we searched for novel chemical entities able to synergize with PAS using a combination screening against growing axenic Mycobacterium tuberculosis. The screening was performed at a sub-inhibitory concentration of PAS on a library of about 100,000 small molecules. Selected hit compounds were analyzed by dose-response and further probed with an intracellular macrophage assay. Scaffolds with potential additive effect with PAS are reported, opening interesting prospects for mechanism of action studies. We also report here evidence of a yet unknown bio-activation mechanism, involving activation of pyrido[1,2-a]pyrimidin-4-one (PP) derivatives through the Rv3087 protein., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
27. PlateEditor: A web-based application for the management of multi-well plate layouts and associated data.
- Author
-
Delorme V, Woo M, Falcão VCA, and Wood C
- Subjects
- Internet, Microarray Analysis methods, Software
- Abstract
Multi-well plates are convenient tools to work with in biology experiments, as they allow the probing of multiple conditions in a compact and economic way. Although both free and commercial software exist for the definition of plate layout and management of plate data, we were looking for a more flexible solution, available anywhere, free from download, installation and licensing constraints. In this context, we created PlateEditor, a free web-based, client-side application allowing rapid creation of even complex layouts, including dose-response curves and multiple combination experiments for any plate format up to 1536 wells. PlateEditor also provides heatmap visualization and aggregation features to speed-up the process of data analysis and formatting for export in other application. Written in pure JavaScript, it is fully open-source, can be integrated in various workflows and has the potential to be extended with more functionalities in the future., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
28. Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent.
- Author
-
Jin G, Mi Kim Y, Lee A, Choi J, Kang S, Seo M, Jea Seo J, Lee S, Kang J, Kim J, Park S, Woo M, Falcão VCA, Lee H, Heo J, Shum D, Park K, Delorme V, and Choi I
- Subjects
- Amides pharmacokinetics, Amides pharmacology, Amides therapeutic use, Animals, Antitubercular Agents pharmacokinetics, Antitubercular Agents pharmacology, Antitubercular Agents therapeutic use, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Stability, Female, Half-Life, Humans, Mice, Mice, Inbred BALB C, Microsomes metabolism, Mycobacterium tuberculosis drug effects, Structure-Activity Relationship, Tuberculosis drug therapy, Tuberculosis microbiology, Tuberculosis pathology, Amides chemistry, Antitubercular Agents chemistry, Thiazoles chemistry
- Abstract
In order to identify anti-tubercular agents with a novel scaffold, commercial libraries of small organic compounds were screened against a fluorescent strain of Mycobacterium tuberculosis H37Rv, using a dual phenotypic assay. Compounds were assessed against bacteria replicating in broth medium, as well as inside macrophages, and thienothiazolocarboxamide (TTCA) scaffold was identified as hit in both assays, with submicromolar inhibitory concentrations. Derivatives of TTCA were further synthesized and evaluated for their inhibitory effects on M.tuberculosis H37Rv. In the present study we report the structure-activity relationship of these TTCA derivatives. Compounds 28, 32 and 42 displayed good anti-tubercular activities, as well as favorable ADME and PK properties. Compound 42 exhibited excellent oral bioavailability in mice with high distribution to lungs, within 1 h. It was found to be efficacious in a dose dependent manner in a murine model of M. tuberculosis infection. Hence, compound 42 is now under evaluation as a potential lead candidate for treatment of tuberculosis., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
29. Reverse poly(ε-caprolactone)-g-dextran graft copolymers. Nano-carriers for intracellular uptake of anticancer drugs.
- Author
-
Delorme V, Lichon L, Mahindad H, Hunger S, Laroui N, Daurat M, Godefroy A, Coudane J, Gary-Bobo M, and Van Den Berghe H
- Subjects
- Antibiotics, Antineoplastic chemistry, Cell Line, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Doxorubicin chemistry, Drug Carriers chemistry, Drug Delivery Systems, Drug Screening Assays, Antitumor, HCT116 Cells, Humans, Micelles, Molecular Structure, Particle Size, Structure-Activity Relationship, Surface Properties, Antibiotics, Antineoplastic pharmacology, Dextrans chemistry, Doxorubicin pharmacology, Nanoparticles chemistry, Polyesters chemistry
- Abstract
A new fully biodegradable "reverse" oligosaccharide-based amphiphilic graft copolymer structure with a hydrophobic backbone and hydrophilic side chains, poly(ε-caprolactone)-g-dextran (PCL-g-Dex) was synthetized. For this purpose, "clickable" propargylated PCL (PCL-yne) and azido-dextran (Dex-N3) were prepared to further synthesize PCL-g-Dex copolymer by a Huisgen's cycloaddition. This "reverse" copolymer architecture self-assembled in biodegradable nano-carriers, in the shape of dynamic polymeric micelles, and were loaded with doxorubicin (Dox) anti-cancer drug. Dox-loaded micelles showed different drug releases depending on the pH. Cytotoxicity tests showed that Dox-loaded micelles can selectively kill colon cancer cells (HCT-116) while they have no cytotoxic effect towards healthy cells (CCD-45SK). Fluorescent micelles based on FITC-labelled PCL-g-Dex copolymer were used for fluorescence imaging and flow cytometry assays. These experiments proved the effective and specific internalization of micelles by cancer cells, whereas healthy cells showed a very poor uptake. These results show that PCL-g-Dex micelles may be a promising Dox nano-carrier in cancer chemotherapy., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
30. Drug Discovery Platform Targeting M. tuberculosis with Human Embryonic Stem Cell-Derived Macrophages.
- Author
-
Han HW, Seo HH, Jo HY, Han HJ, Falcão VCA, Delorme V, Heo J, Shum D, Choi JH, Lee JM, Lee SH, Heo HR, Hong SH, Park MH, Thimmulappa RK, and Kim JH
- Subjects
- Cell Culture Techniques, Cell Differentiation, Cell Line, Cells, Cultured, Gene Expression Profiling, Humans, Macrophages cytology, Macrophages immunology, Phagocytosis immunology, Small Molecule Libraries, Antitubercular Agents pharmacology, Drug Discovery methods, Drug Evaluation, Preclinical methods, Human Embryonic Stem Cells cytology, Macrophages drug effects, Macrophages microbiology, Mycobacterium tuberculosis drug effects
- Abstract
A major limitation in anti-tuberculosis drug screening is the lack of reliable and scalable models for homogeneous human primary macrophage cells of non-cancer origin. Here we report a modified protocol for generating homogeneous populations of macrophage-like cells from human embryonic stem cells. The induced macrophages, referred to as iMACs, presented similar transcriptomic profiles and characteristic immunological features of classical macrophages and were permissive to viral and bacterial infection, in particular Mycobacterium tuberculosis (Mtb). More importantly, iMAC production was amenable to scale up. To evaluate iMAC efficiency in high-throughput anti-tuberculosis drug screening, we performed a phenotypic screening against intracellular Mtb, involving a library of 3,716 compounds that included FDA-approved drugs and other bioactive compounds. Our primary screen identified 120 hits, which were validated in a secondary screen by dose-intracellular and -extracellular Mtb assays. Our confirmatory studies identified a novel anti-Mtb compound, 10-DEBC, also showing activity against drug-resistant strains., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
31. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis.
- Author
-
Nguyen PC, Delorme V, Bénarouche A, Guy A, Landry V, Audebert S, Pophillat M, Camoin L, Crauste C, Galano JM, Durand T, Brodin P, Canaan S, and Cavalier JF
- Subjects
- Animals, Drug Design, Humans, Macrophages drug effects, Macrophages microbiology, Mice, Microbial Sensitivity Tests, Mycobacterium tuberculosis growth & development, RAW 264.7 Cells, Tuberculosis drug therapy, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Mycobacterium tuberculosis drug effects, Oxadiazoles chemistry, Oxadiazoles pharmacology
- Abstract
A set of 19 oxadiazolone (OX) derivatives have been investigated for their antimycobacterial activity against two pathogenic slow-growing mycobacteria, Mycobacterium marinum and Mycobacterium bovis BCG, and the avirulent Mycobacterium tuberculosis (M. tb) mc
2 6230. The encouraging minimal inhibitory concentrations (MIC) values obtained prompted us to test them against virulent M. tb H37Rv growth either in broth medium or inside macrophages. The OX compounds displayed a diversity of action and were found to act either on extracellular M. tb growth only with moderated MIC50 , or both intracellularly on infected macrophages as well as extracellularly on bacterial growth. Of interest, all OX derivatives exhibited very low toxicity towards host macrophages. Among the six potential OXs identified, HPOX, a selective inhibitor of extracellular M. tb growth, was selected and further used in a competitive labelling/enrichment assay against the activity-based probe Desthiobiotin-FP, in order to identify its putative target(s). This approach, combined with mass spectrometry, identified 18 potential candidates, all being serine or cysteine enzymes involved in M. tb lipid metabolism and/or in cell wall biosynthesis. Among them, Ag85A, CaeA, TesA, KasA and MetA have been reported as essential for in vitro growth of M. tb and/or its survival and persistence inside macrophages. Overall, our findings support the assumption that OX derivatives may represent a novel class of multi-target inhibitors leading to the arrest of M. tb growth through a cumulative inhibition of a large number of Ser- and Cys-containing enzymes involved in various important physiological processes., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
32. Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
- Author
-
Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP, Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, and Gref R
- Abstract
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
- Published
- 2018
- Full Text
- View/download PDF
33. Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR- Mycobacterium tuberculosis Strains.
- Author
-
Hameed HMA, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y, Li X, Tan S, Delorme V, Yew WW, Liu J, and Zhang T
- Subjects
- Genome, Bacterial genetics, Humans, Microbial Sensitivity Tests, Mycobacterium tuberculosis classification, Antitubercular Agents therapeutic use, Drug Resistance, Multiple, Bacterial genetics, Extensively Drug-Resistant Tuberculosis microbiology, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis genetics
- Abstract
Tuberculosis (TB) is a formidable infectious disease that remains a major cause of death worldwide today. Escalating application of genomic techniques has expedited the identification of increasing number of mutations associated with drug resistance in Mycobacterium tuberculosis . Unfortunately the prevalence of bacillary resistance becomes alarming in many parts of the world, with the daunting scenarios of multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) and total drug-resistant tuberculosis (TDR-TB), due to number of resistance pathways, alongside some apparently obscure ones. Recent advances in the understanding of the molecular/ genetic basis of drug targets and drug resistance mechanisms have been steadily made. Intriguing findings through whole genome sequencing and other molecular approaches facilitate the further understanding of biology and pathology of M. tuberculosis for the development of new therapeutics to meet the immense challenge of global health.
- Published
- 2018
- Full Text
- View/download PDF
34. Mycobacterium tuberculosis Infection and Innate Responses in a New Model of Lung Alveolar Macrophages.
- Author
-
Woo M, Wood C, Kwon D, Park KP, Fejer G, and Delorme V
- Subjects
- Animals, Autophagy, Cytokines metabolism, Host-Pathogen Interactions, Humans, Immunity, Innate, Lung pathology, Macrophages, Alveolar microbiology, Mice, Mice, Inbred BALB C, Phagosomes metabolism, THP-1 Cells, Macrophages, Alveolar physiology, Mycobacterium tuberculosis physiology, Tuberculosis immunology
- Abstract
Lung alveolar macrophages (AMs) are in the first line of immune defense against respiratory pathogens and play key roles in the pathogenesis of Mycobacterium tuberculosis ( Mtb ) in humans. Nevertheless, AMs are available only in limited amounts for in vitro studies, which hamper the detailed molecular understanding of host- Mtb interactions in these macrophages. The recent establishment of the self-renewing and primary Max Planck Institute (MPI) cells, functionally very close to lung AMs, opens unique opportunities for in vitro studies of host-pathogen interactions in respiratory diseases. Here, we investigated the suitability of MPI cells as a host cell system for Mtb infection. Bacterial, cellular, and innate immune features of MPI cells infected with Mtb were characterized. Live bacteria were readily internalized and efficiently replicated in MPI cells, similarly to primary murine macrophages and other cell lines. MPI cells were also suitable for the determination of anti-tuberculosis (TB) drug activity. The primary innate immune response of MPI cells to live Mtb showed significantly higher and earlier induction of the pro-inflammatory cytokines TNFα, interleukin 6 (IL-6), IL-1α, and IL-1β, as compared to stimulation with heat-killed (HK) bacteria. MPI cells previously showed a lack of induction of the anti-inflammatory cytokine IL-10 to a wide range of stimuli, including HK Mtb . By contrast, we show here that live Mtb is able to induce significant amounts of IL-10 in MPI cells. Autophagy experiments using light chain 3B immunostaining, as well as LysoTracker labeling of acidic vacuoles, demonstrated that MPI cells efficiently control killed Mtb by elimination through phagolysosomes. MPI cells were also able to accumulate lipid droplets in their cytoplasm following exposure to lipoproteins. Collectively, this study establishes the MPI cells as a relevant, versatile host cell model for TB research, allowing a deeper understanding of AMs functions in this pathology.
- Published
- 2018
- Full Text
- View/download PDF
35. ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
- Author
-
Song OR, Queval CJ, Iantomasi R, Delorme V, Marion S, Veyron-Churlet R, Werkmeister E, Popoff M, Ricard I, Jouny S, Deboosere N, Lafont F, Baulard A, Yeramian E, Marsollier L, Hoffmann E, and Brodin P
- Subjects
- A549 Cells, ADP-Ribosylation Factor 1 genetics, ADP-Ribosylation Factor 1 metabolism, Actin Cytoskeleton microbiology, Actin Cytoskeleton ultrastructure, Actins metabolism, GTPase-Activating Proteins antagonists & inhibitors, GTPase-Activating Proteins metabolism, Gene Expression Regulation, Humans, Mycobacterium tuberculosis physiology, Phospholipase D genetics, Phospholipase D metabolism, Polymerization, Pulmonary Alveoli microbiology, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Receptor, Muscarinic M3 genetics, Receptor, Muscarinic M3 metabolism, Shigella flexneri physiology, Signal Transduction, Species Specificity, Yersinia pseudotuberculosis physiology, Actin Cytoskeleton metabolism, Actins genetics, GTPase-Activating Proteins genetics, Host-Pathogen Interactions, Mycobacterium tuberculosis pathogenicity, Pulmonary Alveoli metabolism
- Abstract
The interaction of Mycobacterium tuberculosis (Mtb) with pulmonary epithelial cells is critical for early stages of bacillus colonization and during the progression of tuberculosis. Entry of Mtb into epithelial cells has been shown to depend on F-actin polymerization, though the molecular mechanisms are still unclear. Here, we demonstrate that mycobacterial uptake into epithelial cells requires rearrangements of the actin cytoskeleton, which are regulated by ADP-ribosylation factor 1 (Arf1) and phospholipase D1 (PLD1), and is dependent on the M3 muscarinic receptor (M
3 R). We show that this pathway is controlled by Arf GTPase-activating protein 1 (ArfGAP1), as its silencing has an impact on actin cytoskeleton reorganization leading to uncontrolled uptake and replication of Mtb. Furthermore, we provide evidence that this pathway is critical for mycobacterial entry, while the cellular infection with other pathogens, such as Shigella flexneri and Yersinia pseudotuberculosis , is not affected. Altogether, these results reveal how cortical actin plays the role of a barrier to prevent mycobacterial entry into epithelial cells and indicate a novel role for ArfGAP1 as a restriction factor of host-pathogen interactions., (© 2017 The Authors.)- Published
- 2018
- Full Text
- View/download PDF
36. Phenotypic assays for Mycobacterium tuberculosis infection.
- Author
-
Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, Lafont F, Baulard A, Iantomasi R, and Brodin P
- Subjects
- Animals, Antitubercular Agents pharmacology, Biological Assay methods, Cells, Cultured, Drug Discovery methods, Fluorescence, Macrophages metabolism, Macrophages microbiology, Male, Mice, Mice, Inbred C57BL, RAW 264.7 Cells, Tuberculosis drug therapy, Mycobacterium tuberculosis metabolism, Tuberculosis microbiology
- Abstract
Tuberculosis (TB) is still a major global threat, killing more than one million persons each year. With the constant increase of Mycobacterium tuberculosis strains resistant to first- and second-line drugs, there is an urgent need for the development of new drugs to control the propagation of TB. Although screenings of small molecules on axenic M. tuberculosis cultures were successful for the identification of novel putative anti-TB drugs, new drugs in the development pipeline remains scarce. Host-directed therapy may represent an alternative for drug development against TB. Indeed, M. tuberculosis has multiple specific interactions within host phagocytes, which may be targeted by small molecules. In order to enable drug discovery strategies against microbes residing within host macrophages, we developed multiple fluorescence-based HT/CS phenotypic assays monitoring the intracellular replication of M. tuberculosis as well as its intracellular trafficking. What we propose here is a population-based, multi-parametric analysis pipeline that can be used to monitor the intracellular fate of M. tuberculosis and the dynamics of cellular events such as phagosomal maturation (acidification and permeabilization), zinc poisoning system or lipid body accumulation. Such analysis allows the quantification of biological events considering the host-pathogen interplay and may thus be derived to other intracellular pathogens. © 2017 International Society for Advancement of Cytometry., (© 2017 International Society for Advancement of Cytometry.)
- Published
- 2017
- Full Text
- View/download PDF
37. Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
- Author
-
Queval CJ, Song OR, Carralot JP, Saliou JM, Bongiovanni A, Deloison G, Deboosère N, Jouny S, Iantomasi R, Delorme V, Debrie AS, Park SJ, Gouveia JC, Tomavo S, Brosch R, Yoshimura A, Yeramian E, and Brodin P
- Subjects
- Animals, Mice, Mycobacterium tuberculosis metabolism, Signal Transduction, Mycobacterium tuberculosis pathogenicity, Phagosomes metabolism, Suppressor of Cytokine Signaling Proteins metabolism
- Abstract
Pathogens have evolved a range of mechanisms to counteract host defenses, notably to survive harsh acidic conditions in phagosomes. In the case of Mycobacterium tuberculosis, it has been shown that regulation of phagosome acidification could be achieved by interfering with the retention of the V-ATPase complexes at the vacuole. Here, we present evidence that M. tuberculosis resorts to yet another strategy to control phagosomal acidification, interfering with host suppressor of cytokine signaling (SOCS) protein functions. More precisely, we show that infection of macrophages with M. tuberculosis leads to granulocyte-macrophage colony-stimulating factor (GM-CSF) secretion, inducing STAT5-mediated expression of cytokine-inducible SH2-containing protein (CISH), which selectively targets the V-ATPase catalytic subunit A for ubiquitination and degradation by the proteasome. Consistently, we show that inhibition of CISH expression leads to reduced replication of M. tuberculosis in macrophages. Our findings further broaden the molecular understanding of mechanisms deployed by bacteria to survive., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
- Author
-
Nguyen PC, Delorme V, Bénarouche A, Martin BP, Paudel R, Gnawali GR, Madani A, Puppo R, Landry V, Kremer L, Brodin P, Spilling CD, Cavalier JF, and Canaan S
- Subjects
- Humans, Macrophages metabolism, Macrophages pathology, Tuberculosis metabolism, Tuberculosis pathology, Antitubercular Agents chemistry, Antitubercular Agents pharmacology, Macrophages microbiology, Mycobacterium tuberculosis growth & development, Organophosphorus Compounds chemistry, Organophosphorus Compounds pharmacology, Tuberculosis drug therapy
- Abstract
A new class of Cyclophostin and Cyclipostins (CyC) analogs have been investigated against Mycobacterium tuberculosis H37Rv (M. tb) grown either in broth medium or inside macrophages. Our compounds displayed a diversity of action by acting either on extracellular M. tb bacterial growth only, or both intracellularly on infected macrophages as well as extracellularly on bacterial growth with very low toxicity towards host macrophages. Among the eight potential CyCs identified, CyC
17 exhibited the best extracellular antitubercular activity (MIC50 = 500 nM). This compound was selected and further used in a competitive labelling/enrichment assay against the activity-based probe Desthiobiotin-FP in order to identify its putative target(s). This approach, combined with mass spectrometry, identified 23 potential candidates, most of them being serine or cysteine enzymes involved in M. tb lipid metabolism and/or in cell wall biosynthesis. Among them, Ag85A, CaeA and HsaD, have previously been reported as essential for in vitro growth of M. tb and/or survival and persistence in macrophages. Overall, our findings support the assumption that CyC17 may thus represent a novel class of multi-target inhibitor leading to the arrest of M. tb growth through a cumulative inhibition of a large number of Ser- and Cys-containing enzymes participating in important physiological processes.- Published
- 2017
- Full Text
- View/download PDF
39. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
- Author
-
Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP, Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, and Gref R
- Subjects
- Administration, Inhalation, Animals, Disease Models, Animal, Drug Carriers, Drug Compounding methods, Drug Synergism, Female, Humans, Mice, Mice, Inbred BALB C, Mycobacterium tuberculosis growth & development, Mycobacterium tuberculosis pathogenicity, Nanoparticles administration & dosage, Nanoparticles chemistry, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, RAW 264.7 Cells, Solubility, Treatment Outcome, Tuberculosis, Multidrug-Resistant microbiology, Tuberculosis, Multidrug-Resistant pathology, Tuberculosis, Pulmonary microbiology, Tuberculosis, Pulmonary pathology, beta-Cyclodextrins chemistry, Antitubercular Agents pharmacology, Drug Therapy, Combination methods, Ethionamide pharmacology, Mycobacterium tuberculosis drug effects, Oxadiazoles pharmacology, Piperidines pharmacology, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Pulmonary drug therapy
- Abstract
Tuberculosis (TB) is a leading infectious cause of death worldwide. The use of ethionamide (ETH), a main second line anti-TB drug, is hampered by its severe side effects. Recently discovered "booster" molecules strongly increase the ETH efficacy, opening new perspectives to improve the current clinical outcome of drug-resistant TB. To investigate the simultaneous delivery of ETH and its booster BDM41906 in the lungs, we co-encapsulated these compounds in biodegradable polymeric nanoparticles (NPs), overcoming the bottlenecks inherent to the strong tendency of ETH to crystallize and the limited water solubility of this Booster. The efficacy of the designed formulations was evaluated in TB infected macrophages using an automated confocal high-content screening platform, showing that the drugs maintained their activity after incorporation in NPs. Among tested formulations, "green" β-cyclodextrin (pCD) based NPs displayed the best physico-chemical characteristics and were selected for in vivo studies. The NPs suspension, administered directly into mouse lungs using a Microsprayer®, was proved to be well-tolerated and led to a 3-log decrease of the pulmonary mycobacterial load after 6 administrations as compared to untreated mice. This study paves the way for a future use of pCD NPs for the pulmonary delivery of the [ETH:Booster] pair in TB chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
40. Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.
- Author
-
Jang J, Kim R, Woo M, Jeong J, Park DE, Kim G, and Delorme V
- Subjects
- Antitubercular Agents pharmacology, Bacterial Proteins metabolism, Drug Resistance, Multiple, Bacterial genetics, Imidazoles pharmacology, Microbial Sensitivity Tests, Mycobacterium tuberculosis drug effects, Oxazines pharmacology, Piperidines pharmacology, Pyridines pharmacology, Verapamil pharmacology, Xanthenes pharmacology, Mycobacterium tuberculosis pathogenicity, Tuberculosis metabolism
- Abstract
New and improved treatments for tuberculosis (TB) are urgently needed. Recently, it has been demonstrated that verapamil, an efflux inhibitor, can reduce bacterial drug tolerance caused by efflux pump activity when administered in combination with available antituberculosis agents. The aim of this study was to evaluate the effectiveness of verapamil in combination with the antituberculosis drug candidate Q203, which has recently been developed and is currently under clinical trials as a potential antituberculosis agent. We evaluated changes in Q203 activity in the presence and absence of verapamil in vitro using the resazurin microplate assay and ex vivo using a microscopy-based phenotypic assay for the quantification of intracellular replicating mycobacteria. Verapamil increased the potency of Q203 against Mycobacterium tuberculosis both in vitro and ex vivo , indicating that efflux pumps are associated with the activity of Q203. Other efflux pump inhibitors also displayed an increase in Q203 potency, strengthening this hypothesis. Therefore, the combination of verapamil and Q203 may be a promising combinatorial strategy for anti-TB treatment to accelerate the elimination of M. tuberculosis ., (Copyright © 2017 American Society for Microbiology.)
- Published
- 2017
- Full Text
- View/download PDF
41. Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
- Author
-
Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkönig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Déprez B, Willand N, and Baulard AR
- Subjects
- Animals, DNA metabolism, Ethionamide pharmacology, Humans, Mice, Mutation, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis metabolism, Oxadiazoles pharmacology, Piperidines pharmacology, Protein Binding drug effects, Repressor Proteins antagonists & inhibitors, Repressor Proteins metabolism, Antitubercular Agents pharmacology, Drug Resistance, Multiple, Bacterial drug effects, Ethionamide metabolism, Extensively Drug-Resistant Tuberculosis microbiology, Isoxazoles pharmacology, Mycobacterium tuberculosis drug effects, Spiro Compounds pharmacology
- Abstract
Antibiotic resistance is one of the biggest threats to human health globally. Alarmingly, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have now spread worldwide. Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymatic pathway required for their bioactivation. We have developed drug-like molecules that activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis , circumventing the classic activation pathway in which resistance mutations have now been observed. The first-of-its-kind molecule, named SMARt-420 (Small Molecule Aborting Resistance), not only fully reverses ethionamide-acquired resistance and clears ethionamide-resistant infection in mice, it also increases the basal sensitivity of bacteria to ethionamide., (Copyright © 2017, American Association for the Advancement of Science.)
- Published
- 2017
- Full Text
- View/download PDF
42. High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities.
- Author
-
Heo J, Nam J, Jang J, Shum D, Radu C, Cheng J, Lee H, Suh JW, and Delorme V
- Subjects
- Animals, Antitubercular Agents chemistry, Cell Proliferation drug effects, Cell Survival drug effects, Humans, Macrophages drug effects, Macrophages microbiology, Mice, Microbial Sensitivity Tests, Mycobacterium tuberculosis growth & development, Mycobacterium tuberculosis pathogenicity, Tuberculosis microbiology, Actinobacteria chemistry, Antitubercular Agents pharmacology, Mycobacterium tuberculosis drug effects, Tuberculosis drug therapy
- Abstract
The feasibility and relevance of screening a library of raw actinomycete extracts (ECUM library) for the identification of antituberculosis activities was assessed on 11,088 extracts using a multiple-screening approach. Each extract was first tested at two concentrations against noninfected macrophages as a control, then against Mycobacterium tuberculosis growing in broth medium as well as infecting murine macrophages. The screening results indicated a library of good quality with an apparent low proportion of cytotoxic extracts. A correlation was found between both bacterial assays, but the intracellular assay showed limitations due to low rates of cell survival. Several extracts of interest were highlighted by this multiple screening. A focus on the strain producing the two most effective revealed similarities with known producers of active molecules, suggesting the possibility of selecting relevant extracts using this strategy.
- Published
- 2017
- Full Text
- View/download PDF
43. Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
- Author
-
Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, and Hartkoorn RC
- Subjects
- Anti-Bacterial Agents pharmacokinetics, Cell Enlargement, Drug Discovery methods, Gene Expression Regulation, Bacterial genetics, Mycobacterium smegmatis genetics, Mycobacterium smegmatis metabolism, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis metabolism, Pyrimidines chemistry, Pyrimidines metabolism, Sequence Homology, Amino Acid, Sulfonamides metabolism, Sulfonamides pharmacokinetics, Time-Lapse Imaging, Antitubercular Agents metabolism, Bacterial Proteins genetics, Bacterial Proteins metabolism, Pyrimidines pharmacokinetics
- Abstract
There is an urgent need to discover new anti-tubercular agents with novel mechanisms of action in order to tackle the scourge of drug-resistant tuberculosis. Here, we report the identification of such a molecule - an AminoPYrimidine-Sulfonamide (APYS1) that has potent, bactericidal activity against M. tuberculosis. Mutations in APYS1-resistant M. tuberculosis mapped exclusively to wag31, a gene that encodes a scaffolding protein thought to orchestrate cell elongation. Recombineering confirmed that a Gln201Arg mutation in Wag31 was sufficient to cause resistance to APYS1, however, neither overexpression nor conditional depletion of wag31 impacted M. tuberculosis susceptibility to this compound. In contrast, expression of the wildtype allele of wag31 in APYS1-resistant M. tuberculosis was dominant and restored susceptibility to APYS1 to wildtype levels. Time-lapse imaging and scanning electron microscopy revealed that APYS1 caused gross malformation of the old pole of M. tuberculosis, with eventual lysis. These effects resembled the morphological changes observed following transcriptional silencing of wag31 in M. tuberculosis. These data show that Wag31 is likely not the direct target of APYS1, but the striking phenotypic similarity between APYS1 exposure and genetic depletion of Wag31 in M. tuberculosis suggests that APYS1 might indirectly affect Wag31 through an as yet unknown mechanism., (© 2016 John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
44. STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
- Author
-
Queval CJ, Song OR, Deboosère N, Delorme V, Debrie AS, Iantomasi R, Veyron-Churlet R, Jouny S, Redhage K, Deloison G, Baulard A, Chamaillard M, Locht C, and Brodin P
- Subjects
- Animals, Cell Line, Chemokine CCL4 metabolism, Humans, Immunity, Innate immunology, Interferon-gamma metabolism, Interleukin-10 metabolism, Interleukin-6 metabolism, Macrophages microbiology, Mice, Mycobacterium tuberculosis immunology, Nitric Oxide metabolism, Nitric Oxide Synthase Type II metabolism, RAW 264.7 Cells, Signal Transduction physiology, Tuberculosis immunology, Tumor Necrosis Factor-alpha metabolism, Macrophages metabolism, Nitric Oxide Synthase metabolism, STAT3 Transcription Factor metabolism, Tuberculosis metabolism
- Abstract
Mycobacterium tuberculosis is a successful intracellular pathogen. Numerous host innate immune responses signaling pathways are induced upon mycobacterium invasion, however their impact on M. tuberculosis replication is not fully understood. Here we reinvestigate the role of STAT3 specifically inside human macrophages shortly after M. tuberculosis uptake. We first show that STAT3 activation is mediated by IL-10 and occurs in M. tuberculosis infected cells as well as in bystander non-colonized cells. STAT3 activation results in the inhibition of IL-6, TNF-α, IFN-γ and MIP-1β. We further demonstrate that STAT3 represses iNOS expression and NO synthesis. Accordingly, the inhibition of STAT3 is detrimental for M. tuberculosis intracellular replication. Our study thus points out STAT3 as a key host factor for M. tuberculosis intracellular establishment in the early stages of macrophage infection.
- Published
- 2016
- Full Text
- View/download PDF
45. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
- Author
-
Nikiforov PO, Surade S, Blaszczyk M, Delorme V, Brodin P, Baulard AR, Blundell TL, and Abell C
- Subjects
- Crystallography, X-Ray, Ethionamide pharmacology, Hydrophobic and Hydrophilic Interactions, Inhibitory Concentration 50, Molecular Structure, Small Molecule Libraries pharmacology, Structure-Activity Relationship, Ethionamide chemistry, Mycobacterium tuberculosis drug effects, Repressor Proteins drug effects, Small Molecule Libraries chemistry
- Abstract
With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial transcriptional repressor protein EthR is an attractive therapeutic strategy. Herein we report the use of a fragment based drug discovery approach for the structure-guided systematic merging of two fragment molecules, each binding twice to the hydrophobic cavity of EthR from M. tuberculosis. These together fill the entire binding pocket of EthR. We elaborated these fragment hits and developed small molecule inhibitors which have a 100-fold improvement of potency in vitro over the initial fragments.
- Published
- 2016
- Full Text
- View/download PDF
46. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
- Author
-
Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G, Venturelli A, Savina S, Makarov V, Kolly GS, Molteni E, Binda C, Dhar N, Ferrari S, Brodin P, Delorme V, Landry V, de Jesus Lopes Ribeiro AL, Farina D, Saxena P, Pojer F, Carta A, Luciani R, Porta A, Zanoni G, De Rossi E, Costi MP, Riccardi G, and Cole ST
- Subjects
- Alcohol Oxidoreductases chemistry, Alcohol Oxidoreductases genetics, Alcohol Oxidoreductases metabolism, Antitubercular Agents chemical synthesis, Bacterial Proteins chemistry, Bacterial Proteins genetics, Bacterial Proteins metabolism, Binding Sites, Cell Wall drug effects, Cell Wall enzymology, Crystallography, X-Ray, Drug Discovery, Enzyme Inhibitors chemical synthesis, Gene Expression, Hydrogen Bonding, Microbial Sensitivity Tests, Models, Molecular, Mutation, Mycobacterium tuberculosis enzymology, Mycobacterium tuberculosis growth & development, Protein Binding, Protein Structure, Secondary, Protein Structure, Tertiary, Quinoxalines chemical synthesis, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Small Molecule Libraries chemical synthesis, Structure-Activity Relationship, Alcohol Oxidoreductases antagonists & inhibitors, Antitubercular Agents pharmacology, Bacterial Proteins antagonists & inhibitors, Enzyme Inhibitors pharmacology, Mycobacterium tuberculosis drug effects, Quinoxalines pharmacology, Small Molecule Libraries pharmacology
- Abstract
Phenotypic screening of a quinoxaline library against replicating Mycobacterium tuberculosis led to the identification of lead compound Ty38c (3-((4-methoxybenzyl)amino)-6-(trifluoromethyl)quinoxaline-2-carboxylic acid). With an MIC99 and MBC of 3.1 μM, Ty38c is bactericidal and active against intracellular bacteria. To investigate its mechanism of action, we isolated mutants resistant to Ty38c and sequenced their genomes. Mutations were found in rv3405c, coding for the transcriptional repressor of the divergently expressed rv3406 gene. Biochemical studies clearly showed that Rv3406 decarboxylates Ty38c into its inactive keto metabolite. The actual target was then identified by isolating Ty38c-resistant mutants of an M. tuberculosis strain lacking rv3406. Here, mutations were found in dprE1, encoding the decaprenylphosphoryl-d-ribose oxidase DprE1, essential for biogenesis of the mycobacterial cell wall. Genetics, biochemical validation, and X-ray crystallography revealed Ty38c to be a noncovalent, noncompetitive DprE1 inhibitor. Structure-activity relationship studies generated a family of DprE1 inhibitors with a range of IC50's and bactericidal activity. Co-crystal structures of DprE1 in complex with eight different quinoxaline analogs provided a high-resolution interaction map of the active site of this extremely vulnerable target in M. tuberculosis.
- Published
- 2015
- Full Text
- View/download PDF
47. Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
- Author
-
Delorme V, Song OR, Baulard A, and Brodin P
- Subjects
- Animals, Antitubercular Agents metabolism, Cell Culture Techniques, Dendritic Cells metabolism, Epithelial Cells metabolism, Humans, Macrophages metabolism, Mice, Microscopy, Fluorescence, Permeability, RNA Interference, Antitubercular Agents pharmacology, High-Throughput Screening Assays, Mycobacterium tuberculosis drug effects, Mycobacterium tuberculosis genetics, RNA, Small Interfering genetics
- Abstract
Mycobacterium tuberculosis is able to colonize host cells, and it is now well admitted that the intracellular stage of the bacteria contributes to tuberculosis pathogenesis as well as to making it a persistent infection. There is still limited understanding on how the tubercle bacillus colonizes the cell and what are the factors impacting on its intracellular persistence. Recent advances in imaging technique allow rapid quantification of biological objects in complex environments. Furthermore, M. tuberculosis is a microorganism that is particularly genetically tractable and that tolerates the expression of heterologous fluorescent proteins. Thus, the intracellular distribution of M. tuberculosis expressing fluorescent proteins can be easily quantified by the use of confocal microscopy. Here we describe high-content/high-throughput imaging methods that enable tracking the bacillus inside host settings, taking into account the heterogeneity of colonization.
- Published
- 2015
- Full Text
- View/download PDF
48. Supported inhibitor for fishing lipases in complex biological media and mass spectrometry identification.
- Author
-
Delorme V, Raux B, Puppo R, Leclaire J, Cavalier JF, Marc S, Kamarajugadda PK, Buono G, Fotiadu F, Canaan S, and Carrière F
- Subjects
- Amino Acid Sequence, Electrophoresis, Polyacrylamide Gel, Enzyme Inhibitors chemistry, Humans, Kinetics, Lipase genetics, Lipase metabolism, Magnetic Resonance Spectroscopy, Models, Chemical, Molecular Sequence Data, Molecular Structure, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors pharmacology, Lipase antagonists & inhibitors, Mass Spectrometry methods
- Abstract
A synthetic phosphonate inhibitor designed for lipase inhibition but displaying a broader range of activity was covalently immobilized on a solid support to generate a function-directed tool targeting serine hydrolases. To achieve this goal, straightforward and reliable analytical techniques were developed, allowing the monitoring of the solid support's chemical functionalization, enzyme capture processes and physisorption artifacts. This grafted inhibitor was tested on pure lipases and serine proteases from various origins, and assayed for the selective capture of lipases from several complex biological extracts. The direct identification of captured enzymes by mass spectrometry brought the proof of concept on the efficiency of this supported covalent inhibitor. The features and limitations of this "enzyme-fishing" proteomic tool provide new insight on solid-liquid inhibition process., (Copyright © 2014. Published by Elsevier B.V.)
- Published
- 2014
- Full Text
- View/download PDF
49. A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
- Author
-
Queval CJ, Song OR, Delorme V, Iantomasi R, Veyron-Churlet R, Deboosère N, Landry V, Baulard A, and Brodin P
- Subjects
- Alveolar Epithelial Cells microbiology, Humans, Microscopy, Confocal methods, Mycobacterium tuberculosis genetics, Phenotype, RNA, Small Interfering analysis, RNA, Small Interfering genetics, Tuberculosis microbiology, High-Throughput Screening Assays methods, Mycobacterium tuberculosis isolation & purification
- Abstract
Despite the availability of therapy and vaccine, tuberculosis (TB) remains one of the most deadly and widespread bacterial infections in the world. Since several decades, the sudden burst of multi- and extensively-drug resistant strains is a serious threat for the control of tuberculosis. Therefore, it is essential to identify new targets and pathways critical for the causative agent of the tuberculosis, Mycobacterium tuberculosis (Mtb) and to search for novel chemicals that could become TB drugs. One approach is to set up methods suitable for the genetic and chemical screens of large scale libraries enabling the search of a needle in a haystack. To this end, we developed a phenotypic assay relying on the detection of fluorescently labeled Mtb within fluorescently labeled host cells using automated confocal microscopy. This in vitro assay allows an image based quantification of the colonization process of Mtb into the host and was optimized for the 384-well microplate format, which is proper for screens of siRNA-, chemical compound- or Mtb mutant-libraries. The images are then processed for multiparametric analysis, which provides read out inferring on the pathogenesis of Mtb within host cells.
- Published
- 2014
- Full Text
- View/download PDF
50. Analysis of the discriminative inhibition of mammalian digestive lipases by 3-phenyl substituted 1,3,4-oxadiazol-2(3H)-ones.
- Author
-
Point V, Pavan Kumar KV, Marc S, Delorme V, Parsiegla G, Amara S, Carrière F, Buono G, Fotiadu F, Canaan S, Leclaire J, and Cavalier JF
- Subjects
- Animals, Dogs, Dose-Response Relationship, Drug, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Guinea Pigs, Humans, Lipase metabolism, Models, Molecular, Molecular Structure, Oxadiazoles chemical synthesis, Oxadiazoles chemistry, Recombinant Proteins antagonists & inhibitors, Recombinant Proteins metabolism, Structure-Activity Relationship, Enzyme Inhibitors pharmacology, Lipase antagonists & inhibitors, Oxadiazoles pharmacology
- Abstract
We report here the reactivity and selectivity of three 5-Methoxy-N-3-Phenyl substituted-1,3,4-Oxadiazol-2(3H)-ones (MPOX, as well as meta and para-PhenoxyPhenyl derivatives, i.e.MmPPOX and MpPPOX) with respect to the inhibition of mammalian digestive lipases: dog gastric lipase (DGL), human (HPL) and porcine (PPL) pancreatic lipases, human (HPLRP2) and guinea pig (GPLRP2) pancreatic lipase-related proteins 2, human pancreatic carboxyl ester hydrolase (hCEH), and porcine pancreatic extracts (PPE). All three oxadiazolones displayed similar inhibitory activities on DGL, PLRP2s and hCEH than the FDA-approved anti-obesity drug Orlistat towards the same enzymes. These compounds appeared however to be discriminative of HPL (poorly inhibited) and PPL (fully inhibited). The inhibitory activities obtained experimentally in vitro were further rationalized using in silico molecular docking. In the case of DGL, we demonstrated that the phenoxy group plays a key role in specific molecular interactions within the lipase's active site. The absence of this group in the case of MPOX, as well as its connectivity to the neighbouring aromatic ring in the case of MmPPOX and MpPPOX, strongly impacts the inhibitory efficiency of these oxadiazolones and leads to a significant gain in selectivity towards the lipases tested. The powerful inhibition of PPL, DGL, PLRP2s, hCEH and to a lesser extend HPL, suggests that oxadiazolone derivatives could also provide useful leads for the development of novel and more discriminative inhibitors of digestive lipases. These inhibitors could be used for a better understanding of individual lipase function as well as for drug development aiming at the regulation of the whole gastrointestinal lipolysis process., (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.